The question is what happens if it ends in failure? will they raise another round of equity? will market trust their ability for subsequent clinical trials? IMO debt would still have been a better option. Equity is the most expensive capital and should have been used when phase 2 would have been declared a success.
| Subscribe To Our Free Newsletter |
